

Diagnosing antiphospholipid syndrome: 'extra-criteria' advances

Nature Reviews Rheumatology

13, 548-560

DOI: [10.1038/nrrheum.2017.124](https://doi.org/10.1038/nrrheum.2017.124)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Arterial stenosis in antiphospholipid syndrome: Update on the unrevealed mechanisms of an endothelial disease. <i>Autoimmunity Reviews</i> , 2018, 17, 256-266.	5.8	9
2	Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120.	3.4	42
3	IgA anti- β_2 glycoprotein I antibodies: Experience from a large center. <i>Thrombosis Research</i> , 2018, 162, 38-43.	1.7	17
4	Presence of Immune Complexes of IgG/IgM Bound to β_2 -glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 2644.	4.8	16
5	Laboratory diagnosis of antiphospholipid syndrome. <i>Frontiers in Laboratory Medicine</i> , 2018, 2, 97-101.	1.7	2
6	Active NET formation in Libman-â€œSacks endocarditis without antiphospholipid antibodies: A dramatic onset of systemic lupus erythematosus. <i>Autoimmunity</i> , 2018, 51, 310-318.	2.6	11
7	Antiphospholipid Syndrome and Thrombocytopenia. , 2018, , .		2
8	A Monocentric Cohort of Obstetric Seronegative Anti-Phospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 1678.	4.8	18
9	Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 433-440.	8.0	95
10	Insights into the diagnosis and pathogenesis of the antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 860-866.	3.4	20
11	Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs. <i>PLoS ONE</i> , 2019, 14, e0220033.	2.5	8
12	Suspected systemic rheumatic diseases in patients presenting with cytopenias. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101425.	3.3	5
13	Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 468-477.	2.7	19
14	Does seronegative obstetric APS exist? â€œproâ€•and â€œconsâ€•. <i>Autoimmunity Reviews</i> , 2019, 18, 102407.	5.8	21
15	â€œSeronegative antiphospholipid syndromeâ€™: an update. <i>Lupus</i> , 2019, 28, 273-274.	1.6	16
16	Autoantibodies in Disease Criteria for Systemic Autoimmune Diseases. , 2019, , 81-89.		0
17	Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. <i>Frontiers in Immunology</i> , 2019, 10, 376.	4.8	34
18	Antiphospholipid Syndrome and Renal Allograft Thrombosis. <i>Transplantation</i> , 2019, 103, 481-486.	1.0	14

#	ARTICLE	IF	CITATIONS
19	Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation. <i>Frontiers in Immunology</i> , 2019, 10, 2891.	4.8	8
20	Diagnostic Pitfalls in Immunology Testing. <i>Clinics in Laboratory Medicine</i> , 2019, 39, 567-578.	1.4	3
21	A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome. <i>Immunologic Research</i> , 2019, 67, 478-485.	2.9	11
22	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 940-952.	1.9	19
23	Management of antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 155-161.	0.9	85
24	Treatment of antiphospholipid syndrome beyond anticoagulation. <i>Clinical Immunology</i> , 2019, 206, 53-62.	3.2	23
25	Long-term effect of B-cells depletion alone as rescue therapy for severe thrombocytopenia in primary antiphospholipid syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 741-744.	3.4	12
26	Potential therapeutics for antiphospholipid antibody associated thrombocytopenia: A systematic review and meta-analysis. <i>Modern Rheumatology</i> , 2020, 30, 116-124.	1.8	3
27	Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. <i>Rheumatology</i> , 2020, 59, 1306-1314.	1.9	53
28	Livedo. <i>EMC - AKOS - Trattato Di Medicina</i> , 2020, 22, 1-10.	0.0	0
30	Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS". <i>International Journal of Molecular Sciences</i> , 2020, 21, 8411.	4.1	21
31	The Weight of IgA Anti- β 2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8972.	4.1	23
32	Antiphospholipid antibodies may be associated with uveitis. <i>European Journal of Ophthalmology</i> , 2021, 31, 2446-2450.	1.3	3
33	Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2020, 19, 102641.	5.8	13
34	"Non-criteria" antiphospholipid syndrome: A nomenclature proposal. <i>Autoimmunity Reviews</i> , 2020, 19, 102689.	5.8	37
35	Childhood-onset systemic lupus erythematosus-related antiphospholipid syndrome: A multicenter study with 1519 patients. <i>Autoimmunity Reviews</i> , 2020, 19, 102693.	5.8	18
36	Editorial: Primary Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2020, 11, 1993.	4.8	1
37	Ophthalmologic manifestations in primary antiphospholipid syndrome patients: A cross-sectional analysis of a primary antiphospholipid syndrome cohort (APS-Rio) and systematic review of the literature. <i>Lupus</i> , 2020, 29, 1528-1543.	1.6	14

#	ARTICLE	IF	CITATIONS
38	Genetic Factors in Antiphospholipid Syndrome: Preliminary Experience with Whole Exome Sequencing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9551.	4.1	11
39	Validation of the Particle-Based Multi-Analyte Technology for Detection of Anti-PhosphatidylSerine/Prothrombin Antibodies. <i>Biomedicines</i> , 2020, 8, 622.	3.2	6
40	Non-Criteria Antiphospholipid Antibodies: Risk Factors for Endothelial Dysfunction in Women with Pre-Eclampsia. <i>Life</i> , 2020, 10, 241.	2.4	4
41	Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2274-2286.	3.8	24
42	Antiphospholipid syndrome. <i>Translational Research</i> , 2020, 225, 70-81.	5.0	44
43	Mononeuritis Multiplex Associated With Antiphospholipid Antibodies. <i>Archives of Rheumatology</i> , 2020, 35, 146-148.	0.9	0
44	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , 2020, 29, 1050-1059.	1.6	15
47	Anti-beta-2-glycoprotein I domain 1 identifies antiphospholipid antibodies-related injuries in patients with concomitant lupus nephritis. <i>Journal of Nephrology</i> , 2020, 33, 757-762.	2.0	6
48	Proteins Involved in the Induction of Procoagulant Activity and Autoimmune Response in Patients With Primary Antiphospholipid Syndrome. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090533.	1.7	2
49	Dorsolateral medullary infarction during skin infection by <i>Stenotrophomonas maltophilia</i> in a patient with triple antiphospholipid antibody positivity: a case-based review. <i>Clinical Rheumatology</i> , 2021, 40, 2965-2971.	2.2	2
50	Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients. <i>Rheumatology</i> , 2021, 60, 1106-1113.	1.9	18
51	A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: A retrospective study of 75 patients. <i>Lupus</i> , 2021, 30, 568-577.	1.6	10
52	The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies. <i>Annals of Medicine</i> , 2021, 53, 1328-1339.	3.8	4
53	Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. <i>Current Rheumatology Reports</i> , 2021, 23, 10.	4.7	12
54	Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. <i>Frontiers in Medicine</i> , 2021, 8, 621590.	2.6	1
55	Clinical manifestations in patients with antiphospholipid antibodies: Beyond thrombosis and pregnancy loss. <i>Lupus</i> , 2021, 30, 884-892.	1.6	3
56	Utilizing type I interferon expression in the identification of antiphospholipid syndrome subsets. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 395-406.	3.0	6
57	Cardiolipin interacts with beta-2-glycoprotein I and forms an open conformation—Mechanisms analyzed using hydrogen/deuterium exchange. <i>Protein Science</i> , 2021, 30, 927-939.	7.6	9

#	ARTICLE	IF	CITATIONS
58	Non-Criteria Manifestations of Juvenile Antiphospholipid Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 1240.	2.4	8
59	Beta-2-Microglobulin Deficiency Could Precipitate an Antiphospholipid Syndrome-Like Prothrombotic Situation in Patients With Coronavirus Disease 2019. <i>ACR Open Rheumatology</i> , 2021, 3, 267-276.	2.1	15
60	Chronic relapsing inflammatory optic neuropathy in a patient with triple antiphospholipid antibody positivity. <i>Neurological Sciences</i> , 2021, 42, 3439-3443.	1.9	0
61	Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome. <i>BMC Gastroenterology</i> , 2021, 21, 148.	2.0	3
62	The neurology of lupus. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117419.	0.6	7
63	Anti-Phosphatidylserine/Prothrombin Antibodies in Healthy Women with Unexplained Recurrent Pregnancy Loss. <i>Journal of Clinical Medicine</i> , 2021, 10, 2094.	2.4	11
64	16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1314-1326.	1.6	9
65	Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations. <i>Parkinsonism and Related Disorders</i> , 2021, 88, 116-128.	2.2	10
66	Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665741.	2.4	14
67	B cells in primary antiphospholipid syndrome: Review and remaining challenges. <i>Autoimmunity Reviews</i> , 2021, 20, 102798.	5.8	10
68	Reducing the diagnostic delay in Antiphospholipid Syndrome over time: a real world observation. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 280.	2.7	8
69	CIRCULATING LEVEL OF INTERLEUKIN 6 IN PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME. <i>Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar</i> , 2021, 50, 2271-2280.	0.1	0
70	Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor. <i>Biomedicines</i> , 2021, 9, 899.	3.2	10
71	Assessment of the activity and organ damage in antiphospholipid syndrome. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 101-106.	0.5	1
72	Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data). <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2021, 66, 546-551.	0.5	1
73	Autoimmune Rheumatic Diseases and Vascular Function: The Concept of Autoimmune Atherosclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4427.	2.4	18
76	Hypercoagulable states and pregnancy. <i>Russian Bulletin of Obstetrician-Gynecologist</i> , 2019, 19, 33.	0.3	2
77	Cardiovascular manifestations in patients with antiphospholipid syndrome: issues of diagnosis and management. <i>Hypertension</i> , 2019, .	0.2	0

#	ARTICLE	IF	CITATIONS
79	Case of an unusual diagnosis of primary antiphospholipid syndrome with multiple clinical complications. Oxford Medical Case Reports, 2020, 2020, omaa117.	0.4	0
80	Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome. European Journal of Rheumatology, 2020, 7, 180-183.	0.6	2
81	Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodiesâ€™ types and titersâ€™ cross-sectional study of Serbian cohort. Clinical Rheumatology, 2022, , 1.	2.2	3
82	Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study. Arthritis Research and Therapy, 2022, 24, 33.	3.5	9
83	Primary antiphospholipid syndrome in pediatrics: beyond thrombosis. Report of 32 cases and review of the evidence. Pediatric Rheumatology, 2022, 20, 13.	2.1	2
84	Description of damage in different clusters of patients with antiphospholipid syndrome. Lupus, 2022, 31, 433-442.	1.6	5
85	Care and Treatment for an Antiphospholipid Syndrome-Related Lower Limb Skin Ulcer Unhealed for 7 Years: A Case Report. International Journal of Lower Extremity Wounds, 2022, , 153473462210900.	1.1	0
86	Soluble LILRA3 is aberrantly expressed in antiphospholipid syndrome (APS) and is a potential marker of thrombotic APS. Rheumatology, 2022, 61, 4962-4974.	1.9	3
87	Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management. Autoimmunity Reviews, 2022, 21, 103072.	5.8	10
88	Epidemiology of Antiphospholipid Syndrome in the General Population. Current Rheumatology Reports, 2021, 23, 85.	4.7	49
89	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. Paediatric Drugs, 2022, 24, 13-27.	3.1	5
96	Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. International Journal of Molecular Sciences, 2022, 23, 4946.	4.1	7
97	Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. Rheumatology, 2022, 62, 256-263.	1.9	11
98	Disability and cognitive impairment are interdependent in primary antiphospholipid syndrome. Lupus, 2022, 31, 1104-1113.	1.6	2
99	The Antiphospholipid Syndrome in the Pediatric Population. Advances in Pediatrics, 2022, 69, 107-121.	1.4	2
100	Analysis of Serbian Primary Antiphospholipid Syndrome Patients Confirmed a Strong Association Between Livedo Reticularis and Arterial Thrombosis. Journal of Clinical Rheumatology, 0, Publish Ahead of Print, .	0.9	0
101	Cardiac Magnetic Resonance in Rheumatology to Detect Cardiac Involvement Since Early and Pre-clinical Stages of the Autoimmune Diseases: A Narrative Review. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	3
102	Extra-criteria clinical manifestations of antiphospholipid antibody should not be ignored. Chinese Medical Journal, 0, Publish Ahead of Print, .	2.3	2

#	ARTICLE	IF	CITATIONS
103	Seronegative autoimmune diseases: A challenging diagnosis. <i>Autoimmunity Reviews</i> , 2022, 21, 103143.	5.8	26
104	Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
105	IgA Antiphospholipid Antibodies in Antiphospholipid Syndrome and Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9432.	4.1	8
106	Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
107	Digital ulcers as presenting symptom of secondary antiphospholipid syndrome. <i>JAAD Case Reports</i> , 2022, 29, 1-5.	0.8	1
108	Circulating immune-complexes of IgG/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
109	COVID-19 and the antiphospholipid syndrome. <i>Autoimmunity Reviews</i> , 2022, 21, 103206.	5.8	12
110	Epitope of antiphospholipid antibodies retrieved from peptide microarray based on <sc>R39â€43</sc> of <sc>Î²2â€glycoprotein</sc> I. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, .	2.3	0
111	Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12819.	4.1	4
112	Genetic variation in toll-like receptor 4 gene with primary antiphospholipid syndrome susceptibility: a cohort of Egyptian patients. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	1.0	1
113	Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012â€2021). <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	3
114	Partners in crime: Autoantibodies complicit in COVIDâ€19 pathogenesis. <i>Reviews in Medical Virology</i> , 2023, 33, .	8.3	2
115	Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. <i>European Medical Journal Rheumatology</i> , 0, , 101-111.	0.0	3
116	What you need to know about migraine in Hughes syndrome patients. <i>Lupus</i> , 2023, 32, 319-324.	1.6	2
118	Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management. <i>Drugs</i> , 2023, 83, 117-134.	10.9	3
119	Extra-criteria antiphospholipid antibodies in patients with small vessel brain lesions and clinical manifestations associated with antiphospholipid syndrome. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2023, 32, 107034.	1.6	1
120	Demographic, Clinical, and Serological Characteristics of Antiphospholipid Syndrome Patients From the Anticoagulation Clinic of Hospital Universitario San Vicente FundaciÃ³n, MedellÃn, Colombia. <i>Cureus</i> , 2023, , .	0.5	0
121	Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study. <i>Rheumatology and Therapy</i> , 2023, 10, 649-658.	2.3	0

#	ARTICLE	IF	CITATIONS
122	Pediatric Presentation of Antiphospholipid Syndrome: A Review of Recent Literature With Estimation of Local Prevalence. <i>Seminars in Thrombosis and Hemostasis</i> , 2024, 50, 182-187.	2.7	0
123	Heart Valve Surgery in Antiphospholipid Syndrome Patientsâ€™ Morbidity and Mortality. <i>Life</i> , 2023, 13, 891.	2.4	0
124	Autoimmune encephalitis. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 445-467.	0.1	0
125	Pregnancy complicated with adrenal adenoma causing ACTH-independent Cushingâ€™s syndrome, accompanied by obstetric antiphospholipid syndrome and severe pre-eclampsia: case report and literature review. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
126	Whatâ€™s still unresolved in Hughes syndrome?. <i>Lupus</i> , 0, , 096120332311803.	1.6	0
127	Profile and clinical relevance of non-criteria antiphospholipid antibodies in patients diagnosed with or highly suspected of APS. <i>Rheumatology</i> , 2024, 63, 891-900.	1.9	1
128	Primary and secondary immune thrombocytopenia (ITP): Time for a rethink. <i>Blood Reviews</i> , 2023, 61, 101112.	5.7	3
129	Positive antiphospholipid antibodies: observation or treatment?. <i>Journal of Thrombosis and Thrombolysis</i> , 2023, 56, 301-314.	2.1	2
130	Efforts to Better Characterize â€œAntiphospholipid Antibody Nephropathyâ€ for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report. <i>Journal of Rheumatology</i> , 2024, 51, 150-159.	2.0	6
131	Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at >34 Weeks of Gestation. <i>Journal of Clinical Medicine</i> , 2023, 12, 4516.	2.4	0
132	Systemic lupus erythematosus and antiphospholipid syndrome: past, present, future. <i>Terapevticheskii Arkhiv</i> , 2023, 95, 365-374.	0.8	1
133	Research Status of the Causes of Recurrent Abortion. <i>Traditional Chinese Medicine</i> , 2023, 12, 2059-2065.	0.2	0
134	Antiphospholipid Syndrome: State of the Art of Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 0, , .	2.6	1
135	Anti-Î²2GPI-domain I antibody is associated with extra-criteria manifestations in a large prospective antiphospholipid syndrome cohort in China. <i>Lupus Science and Medicine</i> , 2023, 10, e000924.	2.7	0
136	Antiphospholipid syndrome in cardiovascular disease and cancer. <i>European Journal of Haematology</i> , 2023, 111, 834-843.	2.2	1
137	Cutaneous microvascular occlusion syndrome as the first manifestation of catastrophic lupus-associated antiphospholipid antibody syndrome: a case report. <i>Journal of Medical Case Reports</i> , 2023, 17, .	0.8	0
138	Clinical features, risk factors, and outcomes of diffuse alveolar hemorrhage in antiphospholipid syndrome: A mixed-method approach combining a multicenter cohort with a systematic literature review. <i>Clinical Immunology</i> , 2023, 256, 109775.	3.2	0
139	Ischemic stroke on the background of antiphospholipid syndrome (clinical case). <i>International Neurological Journal</i> , 2023, 19, 137-142.	0.2	0

#	ARTICLE	IF	CITATIONS
140	Risk factors and recurrent thrombosis in primary antiphospholipid syndrome. Exploration of Immunology, 0, , 475-489.	0.3	0
141	Thrombosis and APS: Lessons Learned from Another Black Swan Tale. Lupus, 2023, 32, 1681-1685.	1.6	0
142	Preconception Non-criteria Antiphospholipid Antibodies and Risk of Subsequent Early Pregnancy Loss: a Retrospective Study. Reproductive Sciences, 2024, 31, 746-753.	2.5	0
143	Non-pharmacological rehabilitation interventions for individuals with antiphospholipid syndrome: A scoping review. Lupus, 2024, 33, 101-110.	1.6	0
144	ARID5B-mediated LINC01128 epigenetically activated pyroptosis and apoptosis by promoting the formation of the BTF3/STAT3 complex in β 2GPI/anti- β 2GPI-treated monocytes. Clinical and Translational Medicine, 2024, 14, .	4.0	0
145	Clinical presentation and outcomes in patients with antiphospholipid syndrome-associated adrenal hemorrhage. A multicenter cohort study and systematic literature review. Clinical Immunology, 2024, 260, 109906.	3.2	0
146	Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. Rheumatology, 2024, 63, S124-S136.	1.9	1
147	2023 ACR/EULAR classification criteria in existing research cohorts: an international study. Rheumatology, 0, , .	1.9	0
148	Risk factors for damage accrual in primary antiphospholipid syndrome: A retrospective single-center cohort study. Journal of Autoimmunity, 2024, 144, 103180.	6.5	0
149	Loss of opportunities in the diagnosis and treatment of primary obstetric antiphospholipid syndrome (POAPS): from theory to reality. Clinical Rheumatology, 2024, 43, 1615-1622.	2.2	0
150	Stroke in a Patient With Antiphospholipid Syndrome. Cureus, 2024, , .	0.5	0
151	Hearing loss induced by primary antiphospholipid syndrome, and its improvement by cochlear implant: A clinical case report. Acta Oto-Laryngologica Case Reports, 2024, 9, 16-23.	0.2	0
152	Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Antibodies, 2024, 13, 21.	2.5	0
153	Research Progress in Clinical Observation of Antiphospholipid Syndrome in Obstetrics. Advances in Clinical Medicine, 2024, 14, 234-240.	0.0	0